AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
De Novo Malignancy Following Multi-Organ Heart Transplantation: A National Registry Analysis of Incidence, Tumor Spectrum, and Implications for Oncologic Surveillance
By Oren D, Moeller CM, Fernandez Valledor A et al.
Research Question/Hypothesis: Malignancy is a leading cause of late mortality following heart transplantation (HT). Whether multi-organ HT confers additional de novo malignancy risk, and how this varies across heart-kidney (HK), heart-lung (HL), and heart-liver (HLiv) recipients remains poorly characterized. Using the national UNOS/OPTN registry, we sought to characterize de novo malignancy incidence and identify independent predictors across all HT subtypes. Methods/Approach: We identified 90,883 heart transplant recipients (1987-2026) from the UNOS/OPTN Thoracic Registry: heart-only (n=84,530), heart-kidney (HK; n=4,142), heart-lung (HL; n=1,429), and heart-liver (HLiv; n=782). Non-melanoma skin cancers and recipients with pre-transplant malignancy were excluded. Cumulative incidence was expressed as the proportion of the original cohort developing de novo malignancy by each time point. Multivariable Cox regression adjusted for age, sex, race, diabetes, BMI, donor age, and transplant era. Results/Data: Heart-only recipients had the highest 20-year cumulative malignancy incidence (11.4% of cohort; events=9,051). Despite shorter median follow-up (3.7 years), HK recipients accumulated a disproportionately high 20-year incidence (8.0%), while HL (6.9%) and HLiv (5.5%) had lower absolute burdens, reflecting substantial competing mortality in those groups. Lymphoma/PTLD comprised a markedly higher proportion of malignancies in HL (37.7%) and HLiv (36.6%) compared with heart-only (17.2%) and HK (14.1%). On multivariable Cox regression, multi-organ transplant was independently associated with increased malignancy risk (HR 1.18, 95% CI 1.07-1.30; p<0.001); recipient age (HR 1.62 per SD, 95% CI 1.57-1.66; p<0.001), male sex (HR 1.34, 95% CI 1.27-1.41; p<0.001), and non-white race (HR 0.81, 95% CI 0.77-0.85; p<0.001) were additional significant predictors. Conclusion: Multi-organ transplant was independently associated with an 18% increased risk of de novo malignancy (HR 1.18, p<0.001) after multivariable adjustment. Heart-only recipients carry the highest absolute 20-year malignancy burden, while HK recipients accumulate a disproportionately high rate per unit of follow-up time. PTLD is markedly enriched in HL, implicating intensified immunosuppression in shaping organ-specific tumor biology. Both transplant type and individual patient characteristics should drive oncologic surveillance intensity, with organ-specific screening adaptations for multi-organ heart transplant recipients.